StockData
MacroGenics Inc logo

MacroGenics Inc (MGNX) stock

MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.96−0.02 (-1.01%)

Close on Nov 20, 2026Market cap $124.85MP/E –Yield –

MacroGenics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

MacroGenics's gross profit for the twelve months ending Dec 31, 2025 was $149.50M, up 0.3% year over year. For fiscal 2025 it was $149.50M, up 0.3% from the year before. The highest annual figure on record is $149.50M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$149.50M+0.3%
FY2024Dec 31, 2024$149.12M+156.5%
FY2023Dec 31, 2023$58.13M-60.9%
FY2022Dec 31, 2022$148.59M+98.7%
FY2021Dec 31, 2021$74.80M-28.7%
FY2020Dec 31, 2020$104.88M+63.4%
FY2019Dec 31, 2019$64.19M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$41.23M+115.6%
Q3 FY2025Sep 30, 2025$72.84M-34.1%
Q2 FY2025Jun 30, 2025$6.87M-35.3%
Q1 FY2025Mar 31, 2025$13.19M+49.3%
Q4 FY2024Dec 31, 2024$19.12M+81.1%
Q3 FY2024Sep 30, 2024$110.54M+972.0%
Q2 FY2024Jun 30, 2024$10.62M-17.5%
Q1 FY2024Mar 31, 2024$8.83M-63.8%
Q4 FY2023Dec 31, 2023$10.56M-85.5%
Q3 FY2023Sep 30, 2023$10.31M-73.4%
Q2 FY2023Jun 30, 2023$12.88M-50.1%
Q1 FY2023Mar 31, 2023$24.38M+120.6%
Q4 FY2022Dec 31, 2022$72.98M+452.9%
Q3 FY2022Sep 30, 2022$38.73M+176.7%
Q2 FY2022Jun 30, 2022$25.83M-16.0%
Q1 FY2022Mar 31, 2022$11.05M-34.5%
Q4 FY2021Dec 31, 2021$13.20M-74.9%
Q3 FY2021Sep 30, 2021$14.00M-23.3%
Q2 FY2021Jun 30, 2021$30.74M+51.7%
Q1 FY2021Mar 31, 2021$16.86M+23.3%
Q4 FY2020Dec 31, 2020$52.69M–
Q3 FY2020Sep 30, 2020$18.25M–
Q2 FY2020Jun 30, 2020$20.26M–
Q1 FY2020Mar 31, 2020$13.68M–

More MacroGenics figures

See a number that looks wrong?